Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
ORLOWSKI, Robert Z, STINCHCOMBE, Thomas E, GUERCIOLINI, Roberto, ANDERSON, Jessica K, DEPCIK-SMITH, Natalie D, BHAGAT, Rita, LEHMAN, Mary Jo, NOVICK, Steven C, O'CONNOR, Owen A, SOIGNET, Steven L, MITCHELL, Beverly S, SHEA, Thomas C, BALDWIN, Albert S, STAHL, Stephanie, ADAMS, Julian, ESSELTINE, Dixie-Lee, ELLIOTT, Peter J, PIEN, Christine S
Published in Journal of clinical oncology (15.11.2002)
Published in Journal of clinical oncology (15.11.2002)
Get full text
Journal Article
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
Orlowski, Robert Z., Voorhees, Peter M., Garcia, Reynaldo A., Hall, Melissa D., Kudrik, Fred J., Allred, Tammy, Johri, Anandhi R., Jones, Paul E., Ivanova, Anastasia, Van Deventer, Hendrik W., Gabriel, Don A., Shea, Thomas C., Mitchell, Beverly S., Adams, Julian, Esseltine, Dixie-Lee, Trehu, Elizabeth G., Green, Marie, Lehman, Mary Jo, Natoli, Susan, Collins, Jason M., Lindley, Celeste M., Dees, E.Claire
Published in Blood (15.04.2005)
Published in Blood (15.04.2005)
Get full text
Journal Article
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin
Biehn, Suzanne E, Moore, Dominic T, Voorhees, Peter M, Garcia, Reynaldo A, Lehman, Mary Jo, Dees, E Claire, Orlowski, Robert Z
Published in Annals of hematology (01.03.2007)
Published in Annals of hematology (01.03.2007)
Get full text
Journal Article